share_log

Is Sinocare (SZSE:300298) Using Too Much Debt?

Is Sinocare (SZSE:300298) Using Too Much Debt?

Sinocare (SZSE:300298)是否使用過多的債務?
Simply Wall St ·  07/18 23:17

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. As with many other companies Sinocare Inc. (SZSE:300298) makes use of debt. But the more important question is: how much risk is that debt creating?

作爲投資者,有人認爲波動率而不是債務是考慮風險的最好方式,但禾倫·巴菲特曾經說過:“波動性與風險遠非同義詞。” 當我們考慮一家公司的風險程度時,我們總是想看看它的債務使用情況,因爲債務過載可能導致滅亡。與許多其他公司一樣,新鄉健康產業股份有限公司(SZSE:300298)利用債務。但更重要的問題是:這些債務帶來了多少風險?

When Is Debt Dangerous?

債務何時有危險?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we examine debt levels, we first consider both cash and debt levels, together.

當企業無法通過自由現金流或以優惠價格籌集資本來輕鬆履行這些債務義務時,債務和其他負債變得風險較高。在最壞的情況下,如果企業無法償付其債權人,它可能會破產。雖然這不那麼常見,但我們經常看到負債的企業因爲放貸人迫使他們以困境價格籌集資本而不得不永久稀釋股東。當然,有很多公司使用債務來支持增長,沒有任何負面影響。當我們考慮債務水平時,我們首先要考慮現金和債務水平,兩者結合在一起。

What Is Sinocare's Net Debt?

Sinocare的淨債務是多少?

You can click the graphic below for the historical numbers, but it shows that as of March 2024 Sinocare had CN¥969.1m of debt, an increase on CN¥519.4m, over one year. However, it does have CN¥672.6m in cash offsetting this, leading to net debt of about CN¥296.5m.

您可以點擊下面的圖表查看歷史數據,但是截至2024年3月,新鄉健康產業股份有限公司的債務爲96910萬元,比一年前的51940萬元增加了。然而,它的現金爲67260萬元,抵消了這一點,導致淨債務約爲29650萬元。

big
SZSE:300298 Debt to Equity History July 19th 2024
SZSE:300298債務資本比歷史數據(2024年7月19日)

How Healthy Is Sinocare's Balance Sheet?

新鄉健康產業股份有限公司的資產負債表健康狀況如何?

The latest balance sheet data shows that Sinocare had liabilities of CN¥1.17b due within a year, and liabilities of CN¥1.13b falling due after that. Offsetting these obligations, it had cash of CN¥672.6m as well as receivables valued at CN¥575.4m due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by CN¥1.06b.

最新的資產負債表數據顯示,Sinocare有1170萬元的短期負債和1130萬元的長期負債。抵消這些負債,它有67260萬元的現金以及57540萬元的應收賬款在12個月內到期。因此,它的負債超過了其現金和(短期)應收賬款的總和1060萬元。

Given Sinocare has a market capitalization of CN¥13.6b, it's hard to believe these liabilities pose much threat. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse.

考慮到Sinocare的市值爲136億元,很難相信這些負債會構成多大威脅。不過話說回來,很明顯我們應該繼續監督其財務狀況,以免情況變得更糟。

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

通過查看公司的淨債務與利息、稅、折舊、攤銷前利潤(EBITDA)之比以及它的利息費用(利息覆蓋率)可以衡量一個公司的債務負擔與收益能力。因此,我們考慮將債務與有無計算折舊和攤銷費用的收益相對比。

Sinocare's net debt is only 0.47 times its EBITDA. And its EBIT easily covers its interest expense, being 11.5 times the size. So you could argue it is no more threatened by its debt than an elephant is by a mouse. Fortunately, Sinocare grew its EBIT by 9.3% in the last year, making that debt load look even more manageable. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Sinocare can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Sinocare的淨債務僅爲其息稅折舊及攤銷前利潤(EBITDA)的0.47倍。其EBIt還輕鬆覆蓋了其利息支出,規模爲11.5倍。因此,您可以認爲它不會受到債務的威脅,就像大象不會被老鼠威脅一樣。幸運的是,Sinocare在過去一年中的EBIt增長了9.3%,使得那筆債務負擔看起來更加可控。毫無疑問,我們從資產負債表上了解債務的情況最多。但最終,業務未來的盈利能力將決定Sinocare能否隨着時間的推移加強其資產負債表。因此,如果您關注未來,可以查看此免費報告,其中列出了分析師的盈利預測。

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. During the last three years, Sinocare generated free cash flow amounting to a very robust 81% of its EBIT, more than we'd expect. That puts it in a very strong position to pay down debt.

最後,雖然稅收部門可能喜歡會計利潤,但借款人只接受冰冷的現金。因此,值得檢查的是EBIt有多少是有自由現金流支持的。在過去的三年中,Sinocare產生了非常強大的自由現金流,金額相當於其EBIt的81%,超出了我們的預期。這使其處於非常強有力的償還債務的地位。

Our View

我們的觀點

The good news is that Sinocare's demonstrated ability to convert EBIT to free cash flow delights us like a fluffy puppy does a toddler. And the good news does not stop there, as its interest cover also supports that impression! We would also note that Medical Equipment industry companies like Sinocare commonly do use debt without problems. Overall, we don't think Sinocare is taking any bad risks, as its debt load seems modest. So we're not worried about the use of a little leverage on the balance sheet. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. Be aware that Sinocare is showing 3 warning signs in our investment analysis , you should know about...

好消息是,Sinocare證明了將EBIt轉化爲自由現金流的能力,使我們像毛茸茸的小狗一樣高興。而好消息不止於此,其利息覆蓋率也支持了這種印象!我們也會注意到,像Sinocare這樣的醫療設備行業公司通常會毫無問題地使用債務。總的來說,我們認爲Sinocare沒有承擔任何不良風險,因爲其債務負擔似乎很小。因此,我們並不擔心在資產負債表上使用少量槓桿。毫無疑問,我們從資產負債表上了解債務的情況最多。但最終,每個公司都可能存在超出資產負債表之外的風險。請注意,Sinocare在我們的投資分析中顯示了3個警告信號,您應該知道......

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

當然,如果您是那種喜歡購買沒有負債負擔的股票的投資者,則今天就可以發現我們的獨家淨現金增長股清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論